The efficacy of bempedoic acid [the first ATP-citrate lyase (ACL) inhibitor approved by Food and Drug Administration (FDA)] as a low-density lipoprotein cholesterol (LDL-C)-lowering agent, has validated ACL inhibition as a therapeutic strategy for glycolipid metabolic disorders (
e.g., hyperlipidemia and hypercholesterolemia) [
17,
18]. In our previous study, forrestiacids A and B, the two [4 + 2]-adducts exhibited potent inhibitory effects against ACL, and elicited dual inhibition on the fatty acid and cholesterol syntheses in HepG2 cells [
13]. Continuing our studies on the discovery of novel ACL and lipogenesis inhibitors from natural products, compounds
1 and
2 were evaluated for their ACL inhibitory effects. As illustrated in
Table 2, they both displayed remarkable inhibition on ACL, with 50% inhibiting concentration (IC
50) values of 10.99 and 22.78 µmol/L, respectively. BMS 303141 was used as the positive control (IC
50: 0.46 ± 0.13 µmol/L). Interestingly, bempedoic acid and forrestiacids A–D all are dicarboxylic acid derivatives. Compared with the Diels-Alder adducts forrestiacids A and B (IC
50s < 5 µmol/L) [
13], the Michael adducts (
1, 2), with the absence of a bridged-ring system (Fig. S1), showed relatively weaker inhibitory effects against ACL, although they have the same molecular weight. In addition, the 25
S-isomer (
1) demonstrated more potent inhibitory effect on ACL than its epimer (
2). Interestingly, the 25
S-isomer (
1) also displayed significant inhibition (IC
50: 7.84 µmol/L) against acetyl-CoA carboxylase 1 (ACC1), which is also one of the rate-limiting enzymes in fatty acid synthesis by converting acetyl-CoA to malonyl CoA [
19]. ACC1 has been considered as a potential drug target for glycolipid metabolic disorders (especially for hepatic steatosis). It is worth mentioning that, only slight inhibitory effects on ACL and ACC1 were found for the triterpene precursor neoabiestrine F, with IC
50 values of 24.33 and 24.40 µmol/L, respectively. Taken together, the above findings indicated that the chirality of C-25 in forrestiacids C and D might play an important role in the lipogenesis inhibition of these Michael adducts, which warrants further investigations.